Evaluating Low HER2 Status in Invasive Breast Carcinoma via HER2 Immunohistochemistry, with HER2 FISH Correlation: A Cohort of 112 Patients

INTRODUCTION: Recent trials demonstrated clinically significant benefits in HER2-nonamplified breast cancer with HER2-low expression using novel anti-HER2 antibody-drug conjugates. Thus, HER2-low breast cancer was proposed as a separate diagnostic entity. Herein, we reclassify HER2-negative cancers...

Descripción completa

Detalles Bibliográficos
Autores principales: Ardor, Gokce Deniz, Komforti, Miglena K., Hanna, Helena, Ibanoglu, Onur, Lochala, Abigail, Nassar, Aziza
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10473890/
https://www.ncbi.nlm.nih.gov/pubmed/37664543
http://dx.doi.org/10.1155/2023/9725647

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10473890/
https://www.ncbi.nlm.nih.gov/pubmed/37664543
http://dx.doi.org/10.1155/2023/9725647

Ejemplares similares